Skip to content

Neuropace, Inc. NPCE Change in Lease Liabilities

Change in Lease Liabilities at other companies

ClearPoint Neuro logo
ClearPoint NeuroCLPT
-$391K-67.1%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
-$106K-9.3%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$349K-13.7%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$535K-18.9%

Other financials

Income statement

See full
Revenue$22.1M-2.0%
Gross profit$18.0M+4.1%
Operating income-$5.6M-8.2%
Net income-$6.7M-1.5%
EPS (diluted)-$0.20+4.8%

Balance sheet

See full
Cash & equivalents$15.6M-42.4%
Total debt$70.5M-3.7%
Total equity$14.5M-40.4%
Total assets$98.9M-10.3%

Cash flow

See full
Operating cash flow-$5.9M+21.1%
CapEx$117.0K+216%
Free cash flow-$6.0M+20.0%

Valuation

See full
Market cap$557.77M+63.4%
Enterprise value$612.6M+58.1%
P/S5.6×+1.6×

Profitability

See full
Gross margin78.3%+3.5pp
Operating margin-16.8%-3.5pp
Net margin-21.7%-4.5pp
FCF margin-10.3%-3.5pp

Returns & leverage

See full
Return on equity-111.4%-13.1pp
Debt / equity4.9×+1.9×
Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s change in lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuropace, Inc.'s change in lease liabilities?
Neuropace, Inc. (NPCE) reported change in lease liabilities of -$513K in Q1 2026.
How has Neuropace, Inc.'s change in lease liabilities changed year-over-year?
Neuropace, Inc.'s change in lease liabilities decreased by 14.0% year-over-year, from -$450K to -$513K.
What does change in lease liabilities mean?
Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.